Kinase inhibitors from early research to clinic: Highlights of the Society for Medicines Research Symposium, held on June 24, 2010, at Astrazeneca, Alderley Park Conference Centre, Alderley Park, Macclesfield, UK

Drugs of the Future

Volumn 36, Issue 3, 2011, Pages 249-263

  Allen, J ^a   Collingwood, S P ^b   Ratcliffe, A J ^c  

^a ASTRAZENECA   (United Kingdom)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c Cellzome Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 8055; CP 352664; CP 537555; CP 634558; CP 681560; IMATINIB; JANUS KINASE INHIBITOR; MAGNESIUM CHLORIDE; PROTEIN KINASE INHIBITOR; QTI 571; SMALL INTERFERING RNA; SORAFENIB; TASOCITINIB; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; GENOTOXICITY; HEART OUTPUT; HUMAN; MEDICAL SOCIETY; MOLECULAR INTERACTION; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN CONFORMATION; PULMONARY HYPERTENSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

EID: 84952983080     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.03.1556469     Document Type: Conference Paper

References (28)

1. Fedorov, O., Muller, S., Knapp, S. The (un)targeted cancer kinome. Nat Chem Biol 2010, 6(3): 166-9.
2. Barbie, D.A., Tamayo, P., Boehm, J.S. et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009, 462(7269): 108-12.
3. Sheng, Z., Li, L., Zhu, L.J. et al. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications. Nat Med 2010, 16(6): 671-7.
4. Simard, J.R., Kluter, S., Grutter, C., Getlik, M., Rabiller, M., Rode, H.B., Rauh, D. A new screening assay for allosteric inhibitors of cSrc. Nat Chem Biol 2009, 5(6): 394-6.
5. Morphy, R. Selectively nonselective kinase inhibition: Striking the right balance. J Med Chem 2010, 53(4): 1413-37.
6. Leroy, D., Doerig, C. Drugging the Plasmodium kinome: The benefits of academia-industry synergy. Trends Pharmacol Sci 2008, 29(5): 241-9.
7. Zuccotto, F., Ardini, E., Casale, E., Angiolini, M. Through the "gatekeeper door": Exploiting the active kinase conformation. J Med Chem 2010, 53(7): 2681-94.
8. Liao, J.J. Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors. J Med Chem 2007, 50(3): 409-24.
9. Sielecki, T.M., Johnson, T.L., Liu, J. et al. Quinazolines as cyclin dependent kinase inhibitors. Bioorg Med Chem Lett 2001, 11(9): 1157-60.
10. Berger, D.M., Torres, N., Dutia, M. et al. Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors. Bioorg Med Chem Lett 2009, 19(23): 6519-23.
11. Kornev, A.P., Taylor, S.S. Defining the conserved internal architecture of a protein kinase. Biochim Biophys Acta 2010, 1804(3): 440-4.
12. Greene, N., Aleo, M.D., Louise-May, S., Price, D.A., Will, Y. Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies. Bioorg Med Chem Lett 2010, 20(17): 5308-12.
13. Pesu, M., Candotti, F., Husa, M., Hofmann, S.R., Notarangelo, L.D., O'Shea, J.J. Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005, 203: 127-42.
14. Changelian, P.S., Flanagan, M.E., Ball, D.J. et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003, 302(5646): 875-8.
15. Milici, A.J., Kudlacz, E.M., Audoly, L., Zwillich, S., Changelian, P. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008, 10(1): R14.
16. Karaman, M.W., Herrgard, S., Treiber, D.K. et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26(1): 127-32.
17. Ghofrani, H.A., Seeger, W., Grimminger, F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005, 353(13): 1412-3.
18. Patterson, K.C., Weissmann, A., Ahmadi, T., Farber, H.W. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006, 145(2): 152-3.
19. Souza, R., Sitbon, O., Parent, F., Simonneau, G., Humbert, M. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006, 61(8): 736.
20. Stenmark, K.R., Meyrick, B., Galie, N., Mooi, W.J., McMurtry, I.F. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009, 297(6): L1013-32.
21. Crews, C.M., Alessandrini, A., Erikson, R.L. The primary structure of MEK, a protein kinase that phosphorylates the ERK gene product. Science 1992, 258(5081): 478-80.
22. Deramaudt, T., Rustgi, A.K. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 2005, 1756(2): 97-101.
23. Kohl, N.E., Mosser, S.D., deSolms, S.J. et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993, 260(5116): 1934-7.
24. Eberhard, D.A., Johnson, B.E., Amler, L.C. et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005, 23(25): 5900-9.
25. Davies, H., Bignell, G.R., Cox, C. et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417(6892): 949-54.
26. Solit, D.B., Garraway, L.A., Pratilas, C.A. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439(7074): 358-62.
27. Pratilas, C.A., Taylor, B.S., Ye, Q., Viale, A., Sander, C., Solit, D.B., Rosen, N. (V600E)BRAF is associated with disabled feedback inhibition of RAFMEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009, 106(11): 4519-24.
28. Dry, J.R., Pavey, S., Pratilas, C.A. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 2010, 70(6): 2264-73.